HRP20050281A2 - Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes - Google Patents

Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Info

Publication number
HRP20050281A2
HRP20050281A2 HR20050281A HRP20050281A HRP20050281A2 HR P20050281 A2 HRP20050281 A2 HR P20050281A2 HR 20050281 A HR20050281 A HR 20050281A HR P20050281 A HRP20050281 A HR P20050281A HR P20050281 A2 HRP20050281 A2 HR P20050281A2
Authority
HR
Croatia
Prior art keywords
pyridylmethyl
treatment
medicament
manufacture
myelodysplastic syndromes
Prior art date
Application number
HR20050281A
Other languages
English (en)
Croatian (hr)
Inventor
Han Dugan Margaret
List Alan
Original Assignee
Novartis Ag
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, The Arizona Board Of Regents On Behalf Of The University Of Arizona filed Critical Novartis Ag
Publication of HRP20050281A2 publication Critical patent/HRP20050281A2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050281A 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes HRP20050281A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (1)

Publication Number Publication Date
HRP20050281A2 true HRP20050281A2 (en) 2006-07-31

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050281A HRP20050281A2 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Country Status (22)

Country Link
US (1) US20060128716A1 (https=)
EP (1) EP1545534B1 (https=)
JP (1) JP2006502195A (https=)
KR (1) KR20050074450A (https=)
CN (1) CN100372535C (https=)
AT (1) ATE359789T1 (https=)
AU (1) AU2003299065B2 (https=)
BR (1) BR0314647A (https=)
CA (1) CA2499738A1 (https=)
CR (1) CR7754A (https=)
DE (1) DE60313344T2 (https=)
EC (1) ECSP055700A (https=)
ES (1) ES2285251T3 (https=)
HR (1) HRP20050281A2 (https=)
MX (1) MXPA05003161A (https=)
NO (1) NO20051936L (https=)
PL (1) PL374696A1 (https=)
PT (1) PT1545534E (https=)
RS (1) RS20050228A (https=)
RU (1) RU2353364C2 (https=)
WO (1) WO2004028542A1 (https=)
ZA (1) ZA200502212B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CN1660840A (zh) * 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
EP1248625A2 (en) * 1999-12-06 2002-10-16 Rhode Island Hospital Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Also Published As

Publication number Publication date
DE60313344T2 (de) 2008-01-03
CN100372535C (zh) 2008-03-05
AU2003299065B2 (en) 2006-10-26
JP2006502195A (ja) 2006-01-19
ATE359789T1 (de) 2007-05-15
ES2285251T3 (es) 2007-11-16
ECSP055700A (es) 2005-08-11
ZA200502212B (en) 2006-02-22
KR20050074450A (ko) 2005-07-18
DE60313344D1 (de) 2007-05-31
RS20050228A (sr) 2007-08-03
NO20051936L (no) 2005-06-23
AU2003299065A1 (en) 2004-04-19
CN1684684A (zh) 2005-10-19
WO2004028542A1 (en) 2004-04-08
US20060128716A1 (en) 2006-06-15
EP1545534B1 (en) 2007-04-18
RU2353364C2 (ru) 2009-04-27
RU2005112711A (ru) 2006-02-27
MXPA05003161A (es) 2005-09-12
PL374696A1 (en) 2005-10-31
CA2499738A1 (en) 2004-04-08
BR0314647A (pt) 2005-08-02
PT1545534E (pt) 2007-06-22
EP1545534A1 (en) 2005-06-29
CR7754A (es) 2005-12-02

Similar Documents

Publication Publication Date Title
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1113858T1 (el) Παραγωγα πυριδιν-3-υλιου ως ανοσορυθμιστικοι παραγοντες
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
DK1478329T3 (da) Præparat til oral indgivelse tikl beskyttelse af huden mod lys
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
SMT201200014B (it) Nalmefene cloridrato diidrato.
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
NO20053119D0 (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
DK1861100T3 (da) 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
SE0300457D0 (sv) Novel compounds
HRP20050281A2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060808

Year of fee payment: 4

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn